摘要
目的 探讨地塞米松纳米粒子局部腔内灌注在球囊损伤后再狭窄预防中的应用。方法 球囊损伤兔髂动脉后在损伤局部单次注射 (共 3min)纳米粒子、生理盐水或单纯损伤 ,观察纳米粒子的生物相容性。纳米粒子包被地塞米松在同样动物模型中局部单次给药 ,在术后 3h、3d、7d和 14d采用免疫分析法分别测定局部组织和血浆地塞米松浓度。球囊损伤兔髂动脉 ,分别给予局部纳米粒子 (包被地塞米松 )、静脉纳米粒子 (包被地塞米松 )治疗 ,在术后 2 1d观察损伤血管内膜的增生。结果 纳米粒子局部单次注射并未引起过度的内膜增生。局部单次注射纳米粒子 ,局部组织地塞米松药物浓度在术后 3h >5 0 0 0ng/mg干重组织 ;药物在局部组织持续达 14d之久 ;而血浆药物浓度在局部注射 3小时后后即不能测定。局部纳米粒子 (包被地塞米松 )治疗组与静脉给药组与对照组比较能明显减轻内膜增生 ,且内膜 /中膜比减少 37 9%。结论 纳米粒子具有很好的生物相容性 ;纳米粒子携带地塞米松局部单次给药能够延长局部药物作用时间达 14d ,并能有效减少新生内膜的形成。
Objective To evaluate the tissue compatibility of PLGA Nanoparticles and the effect of local intraluminal infusion of dexamethasone nanoparticles on restenosis after balloon angioplasty Methods PLGA nanoparticles were intraluminally administered after balloon injury in the rabbit iliac model Retention at different time points and biocompatibility of nanoparticles were evaluated Dexamethasone nanoparticles were also used in the same model to observe the effects on restenosis Results The PLGA nanoparticles apperaed to be fully biocompatible In the dexamethasone nanoparticles study, dexamethasone was presented in the treated segment for up to 14 days There is a significant reduction in intima/media ratio in treated animals compared with control Conclusion PLGA nanoparticles have good tissue compatibility Local administration of dexamethasone nanoparticles can retentate in vessel wall for more than 14 days and significantly decreased neointimal formation
出处
《中国介入心脏病学杂志》
2001年第3期115-117,共3页
Chinese Journal of Interventional Cardiology
关键词
血管成形术
再狭窄
纳米粒子
Nanoparticles
Local drug delivery
Restenosis
Angioplasty
